OncoSil Medical Announces Cooperation with Pancreatic Cancer Europe to Advance Treatment Opportunities for Pancreatic Cancer

News

OncoSil Medical Announces Cooperation with Pancreatic Cancer Europe to Advance Treatment Opportunities for Pancreatic Cancer

Sydney, Australia– 8 September 2025 – Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce its cooperation with Pancreatic Cancer Europe (PCE) as part of PCE’s project “Treatment Opportunities for Pancreatic Cancer”.

The collaboration aims to raise awareness of innovative therapies, address treatment disparities across Europe, and improve outcomes for patients with pancreatic cancer.

Pancreatic cancer remains one of the most lethal cancers, with limited treatment options and poor survival rates. Access to therapies varies significantly across European countries, leaving many patients without timely or equitable treatment opportunities. The “Treatment Opportunities for Pancreatic Cancer” project, initiated by PCE, is designed to:

• Highlight the current treatment landscape and gaps in access.
• Promote awareness of innovative therapies and their potential to benefit patients.
• Encourage collaboration among stakeholders to improve equity in care.

Through this cooperation, OncoSil Medical will contribute its expertise in innovative therapies and work with PCE to ensure the patient voice remains central in driving progress.

Nigel Lange, CEO & Managing Director of OncoSil Medical, commented: “We are honoured to work with Pancreatic Cancer Europe on this important initiative. At OncoSil, our mission is to bring innovative treatments to patients who need them most. By cooperating with PCE, we can raise awareness, share knowledge, and collectively help shape a future where more patients have access to life-changing therapies.”

Alfredo Carrato, Founder and Chairperson of Pancreatic Cancer Europe added: “Pancreatic cancer patients across Europe often face disparities in treatment opportunities. Our project ‘Treatment Opportunities for Pancreatic Cancer’ is designed to highlight these gaps and propose actionable solutions. By joining forces with OncoSil Medical, we are combining expertise and resources to make a meaningful difference in patient care.”

This cooperation reflects a shared commitment to driving awareness, advancing treatment access, and improving the lives of patients affected by pancreatic cancer.